Vivani Medical is a preclinical stage biopharmaceutical company which develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable delivery of a range of medicines to treat chronic diseases. Co.'s pipeline programs are: NPM-119, which is in preclinical stage development for the treatment of patients with type 2 diabetes; OKV-119, which is under development for the treatment of obese and diabetic companion cats; NPM-139, which is in feasibility testing for the treatment of patients with obesity; and NPM-159, which is in feasibility testing for the treatment of patients with non-alcoholic steatohepatitis. The VANI YTD return is shown above.
The YTD Return on the VANI YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether VANI YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VANI YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|